Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial -

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Information type: Other primary research
Source: The Lancet Diabetes & Endocrinology
Specialities: Cardiovascular system disorders | Diabetes
Summary
This analysis found evolocumab reduced the primary composite endpoint in patients with (HR 0.83; 95% CI 0.75-0.93; p=0.0008) and without diabetes (0.87; 0.79-0.96; p=0.0052), and it did not increase risk of developing diabetes in those without the disease at baseline.
UKMi comment
The authors of a related Comment say these results reassure us that PCSK9 inhibition is unlikely to have a major effect on diabetes risk. However a small to moderate effect of evolocumab on diabetes risk will only be excluded by the pooling of data from several trials, as was undertaken for statins.
Related links: Comment